An Important Check-Up On Arbutus Biopharma Corp (NASDAQ: ABUS)

Arbutus Biopharma Corp (ABUS) concluded trading on Wednesday at a closing price of $2.92, with 12.42 million shares of worth about $36.28 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 52.08% during that period and on April 3, 2024 the price saw a gain of about 15.87%. Currently the company’s common shares owned by public are about 169.87M shares, out of which, 134.01M shares are available for trading.

Stock saw a price change of 17.27% in past 5 days and over the past one month there was a price change of 7.75%. Year-to-date (YTD), ABUS shares are showing a performance of 16.80% which decreased to -3.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.69 but also hit the highest price of $3.12 during that period. The average intraday trading volume for Arbutus Biopharma Corp shares is 938.77K. The stock is currently trading 12.18% above its 20-day simple moving average (SMA20), while that difference is up 10.77% for SMA50 and it goes to 31.40% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Arbutus Biopharma Corp (NASDAQ: ABUS) currently have 169.87M outstanding shares and institutions hold larger chunk of about 43.84% of that.

The stock has a current market capitalization of $524.11M and its 3Y-monthly beta is at 2.09. It has posted earnings per share of -$0.44 in the same period. It has Quick Ratio of 5.87 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABUS, volatility over the week remained 10.63% while standing at 5.01% over the month.

Analysts are in expectations that Arbutus Biopharma Corp (ABUS) stock would likely to be making an EPS of -$0.11 in the current quarter, while forecast for next quarter EPS is -$0.11 and it is -$0.53 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.13 which is -$0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -1.36% while it is estimated to decrease by -18.83% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on February 02, 2022 offering a Buy rating for the stock and assigned a target price of $5 to it. Coverage by Jefferies stated Arbutus Biopharma Corp (ABUS) stock as a Hold in their note to investors on February 25, 2021, suggesting a price target of $5 for the stock. On December 17, 2020, H.C. Wainwright Initiated their recommendations, while on July 27, 2020, JMP Securities Resumed their ratings for the stock with a price target of $8. Stock get a Neutral rating from Robert W. Baird on July 24, 2020.

Most Popular

Related Posts